Monologue: AI Hits A Wall

In this week's Better Offline monologue, Ed Zitron runs through how Anthropic and OpenAI’s revenue growth is decelerating, and how OpenAI’s pause on model development and collapsing economics create the very real possibility it could collapse. EDITOR’s NOTE: I incorrectly say at the beginning of this that NVIDIA’s earnings were this week. They’re next week. Sorry! Newsletter: What If OpenAI Dies? https://www.wheresyoured.at/what-happens-if-openai-dies/ Save $10 off a year of my premium newsletter: https://edzitronswheresyouredatghostio.outpost.pub/public/promo-subscription/gzqwkv54e1 - I’d be so grateful! YOU CAN NOW BUY BETTER OFFLINE MERCH! Go to https://cottonbureau.com/people/better-offline and use code FREE99 for free shipping on orders of $99 or more. --- LINKS: https://www.tinyurl.com/betterofflinelinks Newsletter: https://www.wheresyoured.at/ Reddit: https://www.reddit.com/r/BetterOffline/ Discord: chat.wheresyoured.at https://discord.com/invite/QUUQUP9szv Ed's Socials: https://twitter.com/edzitron https://www.instagram.com/edzitron https://bsky.app/profile/edzitron.com https://www.threads.net/@edzitron Email Me: [email protected] mailto:[email protected] See omnystudio.com/listener https://omnystudio.com/listener for privacy information.

• 0:00Speaker 00

  This is an iHeart Podcast. Guaranteed Human.

• 0:04Speaker 01

  Snoring, gasping for air during sleep, daytime sleepiness? I'm Shaquille O'Neal and this shouldn't be anybody's experience. Ask your doctor about Zepbound Trisepotide, the first and only FDA-approved prescription medicine for moderate to severe obstructive sleep apnea in adults with obesity.

• 0:20Speaker 02

  Zepbound is a prescription medicine used with a reduced calorie diet and increased physical activity to help adults with moderate to severe obstructive sleep apnea, OSA, and obesity to improve their OSA. Zepbound is approved as a 2.5, 5, 7.5, 10, 12.5, or 15-milligram injection. Zepbound contains trisepotide and should not be used with other trisepotide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children. Don't share needles or pens, or reuse needles. Don't take if allergic to it, or if you or someone in your family had medullary thyroid cancer, or if you've had multiple endocrine neoplasia syndrome type 2. Tell your doctor if you get a lump or swelling in your neck. Stop Zepbound and call your doctor if you have severe stomach pain or a serious allergic

• 1:05Speaker 02

  reaction. Severe side effects may include inflamed pancreas or gallbladder problems. Tell your doctor if you experience vision changes before scheduled procedures with anesthesia, if you're nursing, pregnant, plant-to-be, or taking birth control pills. Taking Zepbound with a sulfonylurea or insulin may cause low blood sugar. Side effects include nausea, diarrhea, and vomiting, which can cause dehydration and worsen kidney problems.

• 1:27Speaker 01

  Talk to your doctor. Call 1-800-545-5979 or visit zepbound.lily.com.

• 1:34Speaker 03

  Small businesses are the pulse of every community. They bring people together, create opportunities, and drive growth. Chase for Business helps business owners like you with personalized guidance and convenient digital tools all in one place. With that guidance and your determination, you can take your business further and help build a brighter future for your community. Learn more at chase.com/business. Chase for Business: Make More of What's Yours. The Chase mobile app is available for select mobile devices. Message and data rates may apply. JPMorgan Chase Bank, N.A., member FDIC. Copyright 2026 JPMorgan Chase & Company.

• 2:16Speaker 04

  Even on my antidepressant, I still struggled with depression symptoms.

• 2:20Speaker 05

  You okay, honey?

• 2:21Speaker 04

  I'm okay, ish. My doctor said adding Rexulti Brexpitrazole could help.

• 2:26Speaker 05

  When added to an antidepressant, Rexulti was proven to significantly reduce depression symptoms, more than an antidepressant alone. Elderly people with dementia-related psychosis have increased risk of death or stroke. Antidepressants may increase suicidal thoughts and actions and worsen depression in children and young adults. Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions. Report fever, stiff muscles, and confusion, which can be life-threatening, or uncontrolled muscle movements which may be permanent. High blood sugar can lead to coma or death. Weight gain, increased cholesterol, unusual urges, dizziness on standing, falls, seizures, trouble swallowing, or sleepiness may occur. Learn about these and other side effects at rexulti.com. Tap ad for PI. Hey, how you doing, honey?

• 3:08Speaker 04

  Okay.

• 3:08Speaker 05

  Okay-ish?

• 3:10Speaker 04

  No-ish. I'm okay, really.

• 3:12Speaker 05

  Ask your doctor about adding Rexulti.

• 3:17Speaker 00

  Coca-Cola. For the big, for the small, the short, and the tall. Peacemakers, risk-takers. For the optimists, pessimists. For long-distance love. For introverts and extroverts. The thinkers and the doers. For old friends and new. Coca-Cola. For everyone. Pick up some Coca-Cola at a store near you.

• 3:49Speaker 04

  Call Zone Media.

• 3:52Speaker 06

  Hello and welcome to this week's Better Offline Monologue. I'm your host, Ed Zitron.

• 4:04Speaker 06

  It's gonna be a long week after a long month after a long few years, so I'm recording this monologue a little earlier than usual, on Tuesday to be specific, which means I don't have thoughts on Nvidia's earnings and won't have them unless, of course, things go really haywire. Now, I've said that, that sounds possible, but I think it's likely the no-IT-load's refused cash dump will continue at least for another quarter there. In any case, we have a far more pressing problem: the deterioration of OpenAI and the AI industry hitting a wall. Last week, OpenAI completed the $7 billion employee share sale, but unlike most employee share sales, OpenAI used its own cash to buy its employee stock at the previously raised valuation of $865 billion.

• 4:47Speaker 06

  A few days later, both Chief Operating Officer and former CFO Brad Lightcap and Chief Revenue Officer Denise Dresser left the company. Dresser had been at the company less than a year and likely walked away from tens of millions of dollars' worth of unvested OpenAI shares. In April, she said that she had, and I quote CNBC, "never seen this level of conviction spread so quickly and consistently within the enterprise industry," though it appears that said conviction didn't spread far enough to keep her at a company that definitely plans to go public sometime in 2027. Unless, of course, it's not quite so definite anymore. Anthropic has dramatically accelerated its plans to go public, with Bloomberg reporting that it is aiming for a September or October listing, though we're yet to see any reporting

• 5:31Speaker 06

  on its actual S1. Now, this is a problem for OpenAI in many ways, but let's get through all the news first. At the very end of last week, Bloomberg also reported that OpenAI was "on track" to hit $40 billion in annualized revenue, $7 billion in annualized run rate less than Anthropic had claimed it hit in May. And yes, you heard that right, I said "on track," which does not mean it hit that number, and no, it did not define run rate, because Bloomberg neglected to do so either, and, well, who needs definitions when you're just talking about bullshit, right? It could mean the last four weeks multiplied by 12 or 13 or really anything. We truly don't know. Everyone seems to use a goddamn different definition of run rate.

• 6:13Speaker 06

  Anyway, then on Monday, Bloomberg reported that Anthropic had hit $65 billion in annualized run rate, which it defined, I shit you not, as "a metric that projects full-year revenue from a shorter period," with no further explanation. Who fucking cares, right? It's only about what's ostensibly meant to be the largest AI company in the world with $300 billion worth of commitments. No need to actually know what you're talking about. No need to say anything further about a market-moving number. No need to do that. Why fucking bother, right? Just put the story in the bag, the hype in the bag. Check, please. We wouldn't really say that at a grocery store. Anyway, in other words, OpenAI had taken four months to not quite catch up with Anthropic,

• 6:56Speaker 06

  only for Anthropic to quickly drop that the race wasn't even close. Regardless, AI boosters immediately got a little anxious because many had been convinced by anonymous sources and questionable data blocks like Yipit that annualized run rates were somewhere between $70 billion and $100 billion. I guess the voices in their heads weren't reliable. Did they try sacrificing an animal? I don't know what these fucking people do. Isn't read, it's just listening to the voices that say, "Sir, yes, $100 billion annualized by end of year. Only the worthy will be able to invest in this IPO, yes." Anyway, said anxiety has spread across the AI industry, with even the most mold-poisoned boosters now fretting that both Anthropic and OpenAI's revenues had slowed down, mostly because they have.

• 7:39Speaker 06

  I'll also add that these numbers, which come from the end of July, are still from the era of token-maxing, where companies were encouraging employees to burn as many tokens as possible with no regard for costs, meaning that growth will invariably slow from here as enterprises cap spending as Walmart and Stripe and multiple others have done. A day after Anthropic crapped in its coffee, OpenAI made the incredible decision to, and I quote, "pause some frontier reinforcement learning training to ensure it can meet the appropriate alignment." A complex way of saying that OpenAI will stop training its latest models for at least the next few weeks to increase safety, connected to the recent incident where an OpenAI model in an incorrectly configured server was able to hack Hugging Face, which is less of a case of it going rogue and more of a case of OpenAI being bad at its job.

• 8:22Speaker 06

  If you tell software to do something, it's gonna try and do it. "Oh, it isn't lined right. You programmed the software poorly." You're wrong here. This isn't the magic of AI. This is the tragic of OpenAI. It's unclear what OpenAI hoped to achieve here, rather than vaguely saying "we care about safety." But from everything I'm seeing on social media and in my inbox, everybody's interpreting this as OpenAI has stopped training new models, which is also the truth, albeit only they claim for two weeks. Maybe, if you believe them. This is a really fucking stupid idea, by the way, or at least was a really fucking stupid idea to announce at a time when everybody has noticed that OpenAI's revenue growth has decelerated. New models and features are effectively the only way for these companies to keep growing,

• 9:05Speaker 06

  and OpenAI is far behind Anthropic, which makes the idea of not doing anything new or much new all the more questionable. OpenAI will, of course, try and spin this as its new models having incredible new abilities it must prepare for. Oh, God, are you gonna say... Look at anyone saying that. You just, you just look at them, you can see the three finger thing from Inglourious Basterds, like, yep, there's someone who doesn't give a shit, there's someone who will scarf down the marketing slot when fed to them. Mmm, yummy. Anyway, this is all very ruminant, but the word on the street is that this is OpenAI hitting a wall and running out of compute to serve inference and train new models, with one person suggesting that Anthropic could follow suit. This does make sense for Anthropic, who got so desperate that its renting capacity

• 9:49Speaker 06

  from Elon Musk's SpaceX and potentially even Meta, but I'm surprised to hear it about OpenAI, who boasted earlier in the year about its massive compute advantage over its competitors. And again, it's also very possible that compute capacity is just not coming online very fast. Sources at Oracle tell me that Stargate Abelheim, which was meant to be finished in June, or maybe the beginning of the year, or maybe the end of the year, it's really unclear at this point, only has three out of eight buildings fully operational, with a fourth in some sort of strange limbo where it's sort of ready but not quite, isn't clear if it's generating any money, and you need money to pay for goods and services, and it's called revenue. Not sure any of these companies fully understand business, but anyway, this could also be a way for OpenAI to save money.

• 10:32Speaker 06

  Per the information, OpenAI spent $8.6 billion on research and development, so model training, in the first quarter of 2026, a number that likely increased in Q2 with the launch of its GPT-5.6 Sol lunar and cyber models. And also, all the compute it was spending accidentally hacking Hugging Face. I swear that's like a felony, right? Like, we don't really, we don't really have, like, laws anymore, I realize, but, anyway. In any case, if Anthropic and OpenAI have truly hit the limits of compute, there's very little that can accelerate it coming online, as every AI data center is the equivalent of cramming an entire city's power, usually spread over a billion or billions or more

• 11:16Speaker 06

  square feet, into around a million square feet, built in the space of two years with constantly increasing costs around memory, specialist talent, specialist materials, and the oil necessary for the gas turbines and the trucks to bring all this shit to the plot of land. And all of this is happening as revenue growth decelerates. If OpenAI and Anthropic can't or won't train new models, that means they'll effectively become model wrapper companies, building products on top of Claude or GPT models in the hopes that they can juice further revenue growth, which is not going to help very much, given that basically every company that builds models, uh, businesses on top of their models is both unprofitable and can barely reach 90 million a month in revenue, which wouldn't even cover a day's worth of inference if it were profitable, which it would not be.

• 11:59Speaker 06

  I'll add that if Anthropic beats OpenAI to IPO, it's unlikely OpenAI will be able to float, or at least have anything approaching an IPO that anyone would actually want to invest in. While both are unprofitable, horribly so, Anthropic has the revenue advantage and slightly better unit economics, which is all it needs to make Sam Altman's public offering untenable. I think it's time to start having a reasonable discussion about the potential collapse of OpenAI and the ramifications for counterparties like Google, Microsoft, Amazon, CoreWeave, Cerberus, and of course Oracle and all associated venture capitalists, in particular Thrive, who has billions of dollars tied up in this company, and of course SoftBank, which needs that liquidity, otherwise, well, they're triple fucked.

• 12:41Speaker 06

  If you're a journalist listening to this, you need to start seriously thinking about and writing about this, because the current state of this company suggests that it has few viable paths to avoid petition. It can't raise much more money. Ninety percent of its last funding round came from Nvidia, Amazon, and SoftBank, none of which are really gonna do a return trip. SoftBank literally can't afford it. Venture capitalists have never offered more than $12 billion of any OpenAI round, and even a We Are The World telethon isn't gonna be enough to keep this pig inflated. What a disgusting way of referring to a company. Anyway, continuing. There is not really a viable path for OpenAI here. I don't know what they do, but it's kind of looking like they're going to die, as I wrote in my newsletter this week, and I'll put a link to that in the, in the notes.

• 13:26Speaker 06

  Either way, I'm off on a flight tomorrow. It's a crazy week. You'll know why soon. It's all good stuff. I love you all. Thank you for listening. I'll be back next week with the wonderful Cal Newport. Catch you then.

• 13:46Speaker 07

  Snoring, gasping during sleep, feeling fatigued? Ask your doctor about Zepbound, terzepatite. The first and only FDA-approved prescription medicine for moderate to severe obstructive sleep apnea, OSA, in adults with obesity. Zepbound is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with moderate to severe obstructive sleep apnea, OSA, and obesity to improve their OSA. Zepbound is approved as a 2.5, 5, 7.5, 10, 12.5, or 15-milligram injection. Zepbound contains terzepatite and should not be used with other terzepatite-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

• 14:30Speaker 07

  Don't share needles or pins, or reuse needles. Don't take if allergic to it, or if you or someone in your family had medullary thyroid cancer, or if you've had multiple endocrine neoplasia syndrome type 2. Tell your doctor if you get a lump or swelling in your neck. Stop Zepbound and call your doctor if you have severe stomach pain or a serious allergic reaction. Severe side effects may include inflamed pancreas or gallbladder problems. Tell your doctor if you experience vision changes before scheduled procedures with anesthesia. If you're nursing, pregnant, plan to be, or taking birth control pills. Taking Zepbound with a sulphonal urea or insulin may cause low blood sugar. Side effects include nausea, diarrhea, and vomiting, which can cause dehydration and worsen kidney problems. Talk to your doctor. Call 1-800-545-5979, or visit zepbound.lily.com.

• 15:16Speaker 08

  I love football season. The games, the rivalries, the food, getting everyone together. No game day feels complete without a trip to Total Wine & More. I can find everything, from cold beer and canned cocktails to wines and spirits for the whole crew. And if I want to bring something different to the watch party, the Total Wine team always has ideas. Plus, it's nice knowing I'm getting the lowest prices. Get your game day lineup ready at Total Wine & More. Spirits are not sold in Virginia and North Carolina. Drink responsibly. B21.

• 15:43Speaker 09

  Being a small business owner isn't just a career, it's a calling. Chase for Business knows how much heart and effort go into building something of your own. Manage all your business finances, from banking to payments to credit cards, all in one place with our digital tools. Plus, access online resources designed to help your business thrive. Learn more at chase.com/business. Chase for Business: Make more of what's yours. The Chase mobile app is available for select mobile devices. Message and data rates may apply. JP Morgan Chase Bank, N.A., member FDIC. Copyright 2026 JP Morgan Chase & Company.

• 16:16Speaker 10

  What if you could have more wins? More support? More sound effects? At LPL Financial, we like the sound of that, because LPL offers more. Advisors, what if you could have more ways to help your clients? Ready to invest? What if you could find an advisor that really understands you? When it comes to your finances, your business, your future, at LPL, we ask, what if you could?

• 16:40Speaker 11

  Paid advertisement. Investing involves risk, including potential loss of principal. LPL Financial, LLC, member FINRA, SIPC. This is an iHeart Podcast. Guaranteed human.